Financial Advocates Investment Management Nektar Therapeutics Transaction History

Financial Advocates Investment Management

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$0.53 - $1.03 $998 - $1,940	-1,884 Reduced 15.15%	10,550 $6,000
Q4 2022 Feb 14, 2023	BUY	$2.03 - $4.28 $25,241 - $53,217	12,434 New	12,434 $28,000
Q2 2022 Aug 12, 2022	SELL	$3.17 - $6.17 $53,110 - $103,372	-16,754 Reduced 57.4%	12,434 $47,000
Q1 2022 May 11, 2022	SELL	$4.16 - $13.72 $337,995 - $1.11 Million	-81,249 Reduced 73.57%	29,188 $157,000
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $957,512 - $1.63 Million	88,413 Added 401.44%	110,437 $1.76 Million
Q3 2021 Nov 04, 2021	BUY	$13.07 - $18.84 $60,945 - $87,850	4,663 Added 26.86%	22,024 $409,000
Q2 2021 Aug 03, 2021	BUY	$16.52 - $20.4 $286,803 - $354,164	17,361 New	17,361 $328,000
Q1 2020 Apr 29, 2020	SELL	$14.47 - $27.96 $205,141 - $396,388	-14,177 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$15.87 - $23.12 $36,072 - $52,551	2,273 Added 19.09%	14,177 $538,000
Q3 2019 Nov 13, 2019	BUY	$16.91 - $36.27 $179,026 - $383,990	10,587 Added 803.87%	11,904 $217,000
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $61,187 - $90,201	1,317 New	1,317 $0

152

131M

92.7K

4.9K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Financial Advocates Investment Management, based on Form 13F filings with the SEC.

Stay updated on Financial Advocates Investment Management with notifications on news.